Proliferating cells need to produce a large amount of energy and, at the same time, need to maintain a constant supply of biosynthetic precursors of macromolecules that are used as building blocks for generating new cells. Indeed, many cancer cells undergo a switch from mitochondrial to glycolytic metabolism and display a truncated tricarboxylic acid cycle to match these specific metabolic requirements of proliferation. Understanding the mechanisms by which cancer cells reprogram various metabolic pathways to satisfy their unique bioenergetic requirements has become an active field of research. Concomitantly, it has emerged that members of a family of orphan nuclear receptors known as the estrogen-related receptors (ERRs), working in concert with members of the PPARg coactivator (PGC)-1 family, act as central transcriptional regulators of metabolic gene networks involved in maintaining energy homeostasis in normal cells. Recent studies have suggested that the PGC-1/ERR transcriptional axis is also important in the metabolic reprogramming of cancer cells. This review focuses on the functional integration of the PGC-1/ ERR axis with known oncogenes and the observation that modulation of the activity of this axis can have both pro-and antiproliferative properties.
Although apparently an inefficient process, cancer cells rely on sustained glycolysis not only for rapid energy production but also for the use of carbon sources to generate intermediate metabolites required for the synthesis of nucleic acids. Moreover, the tricarboxylic acid (TCA) cycle remains functional in most cancer cells and produces intermediates for the biosynthesis of structural precursors like amino acids and fatty acids necessary for making new cells. Since most pyruvate generated from glycolysis is converted to lactate by LDHA-B in cancer cells, the TCA cycle functions as a truncated cycle that needs to be replenished with intermediates in order to function, a process called anaplerosis. Cancer cells utilize glutamine metabolism for feeding the diverted TCA cycle, thus providing the carbon sources necessary for making substrates like ketoglutarate and oxaloacetate used for amino-acid synthesis and citrate for lipid synthesis. 2, 3 Notably, cancer cells also use glutaminolysis and the pentose phosphate pathway to generate abundant reductive power (NADPH) for fatty acid synthesis and cellular detoxification, two important processes to maintain cell proliferation. 2 Therefore, investigating how cancer cells reprogram their metabolism to satisfy their bioenergetic requirements and how this process can be reversed to block tumor growth has become a very active field of research. During the last decade, members of two distinct families of transcriptional regulators, the orphan nuclear receptors known as the estrogen-related receptors (ERRs) and the transcriptional coactivators referred to as the peroxisome proliferator activated receptor g (PPARg)-coactivator-1s (PGC-1s), have been shown to work in concert to regulate mitochondrial biogenesis and metabolic pathways involved in maintaining cellular energy homeostasis. [4] [5] [6] [7] Individually, members of the PGC-1 and ERR families have also been implicated in various oncogenic processes. 8, 9 This review illustrates how modulation of the activity of the PGC-1/ERR transcriptional axis influences the expression of metabolic gene networks in cancer cells. We also present evidences that interplay between the PGC-1/ERR axis and specific oncogenes can contribute to the metabolic reprogramming of cancer cells and of the tumor microenvironment.
PGC-1S AND ERRS: A POTENT FUNCTIONAL RELATIONSHIP
The ERR family of nuclear receptors is named so because it was originally discovered during a cloning exercise aimed at identifying steroid hormone receptors bearing structural similarity with the estrogen receptor (ERa). 10 The family includes three isoforms, ERRa [NR3B1], ERRb [NR3B2] and ERRg [NR3B3] , that possess all the functional domains characteristic of members of the nuclear receptor superfamily including those of the classic estrogen receptor. 11 However, these orphan receptors do not bind natural estrogens nor do they participate in classic estrogen physiology. Instead, functional genomic studies as well as phenotypic analyses of cells, tissues and whole organisms in which the expression of the ERR isoforms was manipulated revealed an essential role for these transcription factors in regulating the expression of metabolic genes either directly or indirectly. 4, 6, 12 The transcriptional activity of the ERRs is ligand-independent and highly relies on the presence of coregulatory proteins, most notably that of PGC-1a and PGC-1b. [13] [14] [15] [16] [17] [18] The PGC-1s likely act as surrogate protein ligands for the ERRs in regulating the expression of mitochondrial genes and of other gene sets involved in the maintenance of energy homeostasis as well as glucose and lipid metabolism. 19 While PGC-1a was originally discovered during a search for proteins able to interact with the nuclear receptor PPARg, 20 the coactivator can interact with a very diverse set of transcription factors including NRF-1, GABPA, YY1 and several other nuclear receptors. 7, 21 In particular, the PGC-1a protein encodes three LxxLL motifs (L1-L3) that generally function as docking sites for nuclear receptors. Indeed, motif L2 allows interaction of PGC-1a with a wide range of nuclear receptors. 14, 17, 22, 23 In contrast, the more atypical L3 motif acts as a high affinity specific anchor for the ERRs. 14, 17, 24 Interestingly, it has been shown that PGC-1a L2-L3 mutants engineered to specifically interact with the ERRs have similar transcriptional outputs to that of wild-type PGC-1a. 25 This observation suggests that the mechanism privileging specific physical interactions between the PGC-1s and the ERRs has clear biological significance. 21, 25, 26 Indeed, several studies have shown a functional codependency between the PGC-1s and the ERRs for their ability to control the expression of target genes. 4, 18, 27, 28 
EXPRESSION OF ERRS AND PGC-1S IN HUMAN TUMORS
The three ERR isoforms are widely but differentially expressed in embryonic and adult tissues. 11 The expression pattern of the three ERR isoforms is characterized by high levels in tissues with greater energy demands such as the heart, skeletal muscles and kidneys. [29] [30] [31] [32] [33] The widespread expression profile of ERRs in normal tissues combined with the observation that the ERRs can dictate the fate of cells of various origins [34] [35] [36] [37] advocates that deregulation of ERR transcriptional signaling could play a role in various types of cancer. Indeed, altered expression of all three ERR isoforms has been reported in human tumors of various origins (Table 1 and references therein). The expression of ERRa has mostly been studied in breast tumors where it is often highly expressed. The expression of ERRa in samples from various cohorts of breast cancer patients correlates positively with the expression of the oncogene ERBB2 and of the coactivator SRC-3 (also known as Amplified in Breast Cancer 1, AIB1), as well as with node status, increased risk of recurrence, resistance to the antiestrogenic drug tamoxifen and metastatic status at both the protein and mRNA expression levels ( Table 1) . In some studies, the expression of ERRa is also inversely correlated to that of ERa and the progesterone (PR) receptors, which are considered good prognostic markers in breast cancer. Taken together, the patterns of expression of these factors indicate that ERRa is an unfavorable prognostic marker in breast tumors. However, on its own, the mRNA expression of ERRa in breast tumor microarray data sets is in general not a good predictor of patient survival. 38 ERRb expression was also detected in breast tumors and associates with that of ERb but the implications of these observations are not clear. The expression of ERRg was also reported as high in some breast tumor samples and its expression was positively associated with PR and ERBB4 expression, lymph node-negative status as well as with increased ERa signaling, all occurrences considered as good prognostic markers. Therefore, in contrast to ERRa, ERRg is considered a favorable marker in breast tumors and accordingly, the expressions of both receptors are inversely correlated.
In ovarian tumors, the expression of ERRa correlates with high grade and with the presence of the CA-125 antigen and is thus associated with reduced survival rates ( Table 1) . While the expression of ERRg was also found to be high in ovarian tumors versus normal adjacent tissue, its expression correlates with FIGO stage and, similarly to breast cancer, with improved survival rates. In contrast to most cancers, ERRb expression can be detected in ovarian tumors but only at low levels and without correlation with disease status or patient survival. In prostate tumors, ERRa is highly expressed by immunohistochemistry and correlates with Gleason score and with reduced survival rates. In contrast, the expression levels of both ERRb and ERRg surveyed by immunohistochemistry were found to be low in tumors with reduced survival rates, suggesting that they act as favorable markers in prostate tumors. Finally, the gene and protein expression levels of ERRa in uterine tumors are inconsistent, with reports of both low and high expression levels associated with myometrial invasion. The expression of ERRg was found high in uterine tumors versus adjacent normal tissue and to correlate with myometrial invasion.
In a manner similar to the ERRs, the PGC-1s are highly expressed in tissues with high energy demand and PGC-1a expression is increased upon exposure to diverse physiological stresses. 39 However, less is known about the expression of PGC-1 isoforms in human tumors (Table 1 ). In general, the expression of PGC-1a is reduced in most tumors compared with normal tissue, including those originating from the breast, colon, ovaries and liver. Nevertheless, a report suggested that while the expression of PGC-1a is not significantly different in breast tumors versus normal adjacent tissues, a decrease in PGC-1a in tumors was associated with a poor prognosis. 40 In contrast, PGC-1a levels were shown to be elevated in endometrial cancer and renal tumors. It should be noted that the expression levels of PGC-1a are generally low and exhibit dynamic regulation by many environmental factors. These factors could contribute to the variability and to the technical challenges in assessing PGC-1a expression in human tumors. The levels of PGC-1b in human tumors have yet to be examined in a meaningful manner.
A recent comprehensive study examining genetic alteration in 510 human breast tumors revealed significant amplification and deletion in the genomic loci containing the genes ESRRA (11q13.1), ESRRB (14q24) and ESRRG (1q36) coding for all three isoforms of ERRs, particularly in the luminal A and B subtypes. 41 Similarly, both amplification and deletion of the PPARGC1B locus (5q23) and deletion of the PPARGC1A locus (4p14-16) have been observed in a significant number of breast tumors. However, this study did not report any mutation or epigenetic abnormality associated with these genes. Nevertheless, in a previous study, genetic variants in PPARGC1A and PPARGC1B have been reported in breast tumors and were associated with familial breast cancer susceptibility. 42 
EXPRESSION OF PGC-1/ERR TARGET GENES IN HUMAN TUMORS
The vast majority of the target genes of the PGC-1/ERR axis have been identified using functional genomics in various cell lines. Intersecting the PGC-1/ERR target genes with gene expression data from human breast tumors validated their biological relevance. Indeed, examination of the expression profile of ERRa direct target genes identified by ChIP-on-chip in MCF-7 and SkBr3 cells in expression data from cohorts of human breast tumor samples separates ERRa target genes into four clusters that recapitulate the previously established breast tumor subtypes. 43 This result not only implies that ERRa signaling is breast tumor subtype specific but also suggests that ERRa could contribute to the establishment of intra-tumor heterogeneity by regulating distinct sets of genes, a phenomenon that is linked to clinically important aspects of human cancers such as prognosis, risk of metastasis and therapeutic response. 44 In addition, the study by Deblois et al. 43 identified 86 ERRa target genes whose expression in cohorts of human breast tumor samples significantly associated with clinical outcome. Of note, the expression of several genes included in this prognosis-associated signature were significantly affected by treatment with the ERRa inverse agonist XCT-790, suggesting that the expression of ERRa targets that are important to breast cancer etiology could be acquiescent to pharmacologic regulation. Using a similar approach, Chang et al. 38 examined the expression patterns of ERRa target genes identified upon coactivation with the ERR-selective PGC-1a mutant in a human primary mammary epithelial cell line, throughout clinical data sets. This study showed that the expression of a subset of the genes regulated by the PGC-1/ERR axis is associated with shorter diseasefree survival in patients. In agreement with the work of Deblois et al., 43 this signature related to the PGC-1/ERR activity predicts the ability of XCT-790 to inhibit the proliferation of breast cancer cells in culture. Therefore, while the sole expressions of ERRs or PGC-1s are not systematically predictive of outcome in tumors, interrogation of the expression of their target genes is more informative for predicting outcome.
THE PGC-1/ERR AXIS TARGETS METABOLIC GENES AND REGULATORS IN CANCER CELLS
A decade after the initial identification of Acadm as the first target gene of ERRa, 45, 46 functional genomic experiments in mouse heart, liver, kidneys and embryonic stem cells have irrevocably established the PGC-1/ERR axis as the main regulator of gene networks implicated in mitochondrial biogenesis and energy metabolism. 4, 5 Indeed, in normal cells, ERRa was found to bind to the promoters of virtually all genes involved in glycolysis, pyruvate metabolism, TCA cycle and of most genes encoding the five complexes of the oxidative phosphorylation pathway. The all-embracing control of metabolic target genes exerted by ERRa led to the definition of the 'ERR regulon' in mouse liver. 13 The results of genome-wide location analyses were often correlated with expression data showing that functional binding of ERRs to promoters is associated with the modulation of expression of the metabolic target genes and that PGC-1a and/or PGC-1b were required for the induction of these target genes.
Similar results were obtained for ERRa in human cancer cell lines. ChIP-on-chip experiments by Deblois et al. 43 identified a total of 1026 ERRa binding sites in the extended promoter regions of target genes in MCF-7 and SKBr3 human breast cancer cells. The genes associated with these binding events are significantly enriched for various metabolic-related functions including oxidative phosphorylation, TCA cycle and aerobic respiration. 43 Of particular interest, ERRa was found to bind to the promoters and to regulate the expression of metabolic genes that have been previously linked to cancer development and progression including genes involved in glycolysis (for example, LDHA, PGM1, PFKM), the TCA cycle and mitochondrial metabolism (for example, SDHB, IDH1, IDH2), OXPHOS (for example, several components of mitochondrial complex I, COX1), amino-acid metabolism (for example, PHGDH, GLS2) and lipid synthesis (for example, ACLY, FASN). 43, [47] [48] [49] Likewise, functional location analyses experiments revealed recruitment of PGC-1b to the promoter of target genes shared with ERRa and involved in regulating all aspects of energy metabolism in breast cancer cells (Figure 1) . Analysis of microarray Abbreviations: ERR, estrogen-related receptor; IHC, immunohistochemistry; PGC, PPARg coactivator.
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expression data in MCF-7 breast cancer cells transduced with an adenovirus encoding a PGC-1a mutant that selectively activates the ERRs also showed that the majority of genes regulated in this context are involved in various aspects of energy metabolism and in the response to oxidative stress. 25 Disruption of ERRa activity by a specific antagonist molecule (compound A) in both MCF-7 and BT-20 human breast cancer cell lines also led to modulation of gene networks involved in energy metabolism. 50 The PGC-1/ERR axis was found to regulate important genes involved in various tumorigenic processes than can also mediate metabolic reprogramming. For instance, ERRa and PGC-1b bind to the promoters and enhancers of genes located in the ERBB2 amplicon on human chromosome 17q12-21 and regulate their expression in breast cancer cells and in mammary tumors in mice. 51 ERBB2 expression stimulates glucose uptake, NADPH production by the pentose phosphate pathway and fatty acid oxidation, which result in a reduction in oxidative stress in mammary epithelial cells. 52 The levels of the ERBB2 protein are themselves regulated by nutrient availability, including glucose. 53 Functional genomics studies in breast cancer cells have also shown that ERRa can regulate the expression of genes encoding proteins involved directly or indirectly in the control of metabolic genes processes like c-Myc, c-Jun, p53, VEGF (vascular endothelia growth factor) and b-catenin. 43 The list of ERR target genes also includes several other genes involved in growth factor signaling, kinases and adaptor proteins that have also been implicated in the metabolic reprogramming of cancer cells.
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THE PGC-1/ERR AXIS AND BIOENERGETIC REGULATION OF CANCER CELLS As mentioned previously, reprogramming of cancer cell metabolism appears to be fundamental to the establishment and maintenance of tumorigenesis. Recent studies have highlighted a dynamic interaction between glycolysis, mitochondrial function and biosynthetic pathways in cancer. 54 Upregulation of enzymes controlling glycolysis, in particular expression of PKM2, a splicing variant of pyruvate kinase found in muscle, is often observed in cancer cells. 55 ERRa and ERRg bind to the promoter and regulate the expression of these glycolytic enzymes in both normal tissues and cancer cell lines. 13, 30, 32, 43, [56] [57] [58] In normal tissues, the presence of ERRa is indeed necessary for carbohydrate-based energy production in the heart in response to cardiac stress 59 and in Drosophila to direct a metabolic switch to glycolysis, pentose phosphate pathway and other aspects of carbohydrate metabolism to support developmental growth. 12 ERRa is indispensable for the ability of the hepatocellular carcinoma HepG2 cell line to switch from oxidative to glycolytic metabolism when mitochondrial oxidative phosphorylation is unable to meet their energy demand. 13 It is therefore apparent that ERRa possesses the necessary functional attributes to induce the Warburg effect in cancer cells.
Nevertheless, the involvement of the PGC-1/ERR axis in the metabolic reprogramming of cancer cells likely exceeds the control of glycolysis. Indeed, ChIP-on-chip data in breast cancer cells revealed binding of ERRa to the extended promoter of the enzymes involved in the control of glutamine metabolism 43 (unpublished data), while activation of the PGC-1/ERR axis with an ERR-specific mutant of PGC-1a supports functional regulation of these target genes. 25 Moreover, the recruitment of ERRa to the promoter of all the enzymes involved in the TCA cycle, lipid and amino-acid synthesis and the control of their expression by ERRa in breast cancer cells could contribute to the anaplerotic process that sustains the truncated TCA cycle and to the biosynthesis of building blocks. 25 Therefore, reprogramming of cancer cell metabolism by the PGC-1/ERR axis likely extends beyond sustaining the Warburg effect. This dual activity of ERRa reflects its complex involvement in regulating multiple aspects of cancer cell metabolic reprogramming.
In normal tissues, the presence of ERRg is required for the heart to switch from fetal carbohydrate metabolism to a post-natal program enabling fatty acid oxidation as the main energy source. 58 The dependency on ERRg for adult heart development supports a role as a regulator of the switch towards oxidative metabolic functions in cancer cells as well, a metabolic phenotype associated with better prognosis. Indeed, inhibition of ERRg expression by miR-378* in both human and murine mammary cancer cells leads to a reduction in TCA cycle gene expression and oxygen consumption with a concomitant increase in lactate production and cell proliferation. 57 Furthermore, ectopic expression of ERRg in mammary carcinoma cells enhances oxidative metabolism and inhibits the growth of tumor xenografts in vivo.
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The metabolic state associated with cell proliferation involves oxidative metabolism and the consequent production of ROS (reactive oxygen species) that are detrimental to the cells and can induce caspase-mediated apoptosis. 61 Tumor cells can evade this protection mechanism and therefore ensure continued proliferation by activating detoxification mechanisms that remove the accumulated ROS. Components of the ERR/PGC axis have been shown to bind to the promoter of and to regulate the expression of a number of enzymes involved in the response to oxidative stress such as superoxide dismutase (SOD2) and of the detoxification enzyme glutathione S-transferase M1 (GSDM1) in breast cancer cells. 25, 43 In addition, increased levels of ERRa and PGC-1a, accompanied by enhanced protection against the deleterious effects of oxidative stress, have been observed in a model of breast cancer brain metastasis. 62 It should also be noted that PGC-1a has been shown to be a powerful regulator of ROS metabolism in the context of a model of neurodegenerative disease. 63 The levels of NADPH are also important for this process since the detoxification process by glutathione reductase requires NADPH. By regulating the expression of cell detoxification enzymes like SOD2 and GSDM1 and enhancing NADPH production through glycolysis and glutamine metabolism, the PGC-1/ERR axis can provide growing cells with an anti-oxidant defense mechanism and control the oxidative stress damage induced on proliferating cells PGC-1b IS A KEY COMPONENT OF PGC-1/ERR AXIS IN CANCER CELLS As introduced above, lower expression of PGC-1a in tumors was associated with poor prognosis 40 while the expression of PGC-1b but not PGC-1a or PPRC1, the third member of the PGC-1 family, correlated with the expression of ERRa in a large panel of breast cancer cell lines. 38 These observations suggest that the activity of the PGC-1/ERR axis in cancer cells might be driven by the PGC-1b isoform. Indeed, evidence is rapidly accumulating that points to PGC-1b as a key component of the PGC-1/ERR axis in cancer cells. First, recruitment of PGC-1b, but not that of the SRC-3 (AIB1) coactivator, was observed at genomic regions occupied by ERRa in SKBr3 cells. 43 Second, ChIP-on-chip experiments examining PGC-1b recruitment at specific genomic locations showed that PGC-1b recruitment occurs at sites shared with ERRa in breast SKBr3 cells and close to genes associated with metabolic processes (Figure 1 ). Recruitment of PGC-1b at common sites was lost upon depletion of ERRa while knockdown of PGC-1b led to reduced expression of ERRa target genes, including those located within the ERBB2 amplicon. Knockdown of PGC-1b also led to a significant decrease in SKBr3 cell proliferation. 51 Third, PGC-1b is a component of a feed forward loop dictating the transcriptional output of the distinct ERR isoforms in human and murine mammary tumor cells. 57 This regulatory loop includes miR-378*, that is embedded within the gene encoding PGC-1b and targets ERRg to inhibit its expression. Increased expression of miR-378* correlates with progression of breast cancer toward more advanced stages of the disease. Since miR-378* and PGC-1b were shown to be coexpressed, 57 it can be inferred that PGC-1b expression follows the same trend during breast cancer progression. Fourth, knockdown of PGC-1b in SKBr3 cells also led to a decreased expression of PGC-1/ERR target genes associated with an unfavorable outcome as well as a significant reduction in the growth of these cells, 38 as previously observed. 43, 51 Taken together, these results indicate a prominent role for PGC-1b in determining the activity of the PGC-1/ERR axis in human breast tumors.
ONCOGENIC REGULATION OF THE PGC-1/ERR AXIS
The activity of the PGC-1/ERR axis is clearly linked to the cancer phenotype, indicating that oncogenic signals could be involved in the regulation of the expression or activity of its components. Early studies showed that the expression of ERRa correlates with the presence of ERBB2 64 and that the epidermal growth factor/ ERBB2 signaling axis regulates the transcriptional activities of ERRa. 65, 66 However, very little is known about the regulation of the expression of ERRa in cancer cells. On the other hand, the expression of PGC-1b has been shown to be dependent on c-Myc in renal carcinoma cells 67 and likewise, induction of c-Myc expression by IGF-1 and heregulin precedes an increase in PGC1b mRNA in MCF-7 breast cancer cells. 38 In addition, treatment of these cells with a c-Myc inhibitor prevents the induction of PGC-1b mRNA by IGF-1 and heregulin, and c-Myc binds to a regulatory region within the first intron of the PGC-1b gene. 38 Furthermore, binding of c-Myc to this site is upregulated upon treatment with IGF-1 or heregulin 38 while knockdown of ERBB2 in BT-474 breast cancer cells inhibits PGC-1b expression. 57 These results are consistent with the knowledge that the ERBB2 signaling pathway can regulate c-Myc expression at the transcriptional and translational levels. 68, 69 However, control of c-Myc expression is multifaceted and therefore it should not be expected that c-Mycdirected increase in activity of the PGC-1/ERR axis is limited to ERBB2-positive tumors. Indeed, differential ERRa transcriptional activity can be observed in all subtypes of breast cancer. 43 
THE PGC-1/ERR AXIS IN INVASION, ANGIOGENESIS AND METASTASIS
One of the hallmarks of aggressive tumors is their metastatic ability dictated by their invasion and migration potential as well as their capability to establish tumor vascularization. The glycolytic state that prevails in tumor cells reflects a metabolic profile known to favor tumor angiogenesis, invasion and migration. 70 Since ERRa could contribute to the metabolic reprogramming of cancer cells, it can be envisioned that it also affects metastatic potential of these cells. In normal tissues, decreased expression of ERRa was shown to affect cell migration during zebrafish gastrulation in vivo. 71 It also affects breast cancer cell migration in vitro, albeit without affecting proliferation rates. 25 The absence of ERRa is also able to impair tumorigenic potential in aggressive breast cancer cells xenograft in nude mice. 25 These observations are supported by the finding that ERRa and its coactivator PGC-1a bind to the promoter of and regulate the expression of VEGF, an important factor involved in tumor angiogenesis and invasion. 72, 73 The PGC-1/ERR axis has also been shown to be a potent inducer of VEGF 53 and to promote angiogenesis 72 in muscle. In addition, the kinase suppressor of ras1 (KSR1) is able to regulate ERRa and PGC-1a to promote oncogenic ras-dependent and anchorage-independent growth of cancer cells. 74 ERRa has also been shown to regulate the expression of HIF in breast cancer cells and to associate with the HIFa/b heterodimer to promote its transcriptional activity on angiogenic and migratory target genes like VEGF. 75 ERRa is also thought to cooperate with HIF to induce the metabolic reprogramming towards the metastatic-promoting glycolytic state in tumor cells. 75 The PGC-1/ERR axis also regulates the expression of WNT11, a process that involves ERRa in a transcriptional complex with b-catenin. 76 Ablation of either ERRa or b-catenin expression decreases the migratory capacity of cancer cells of various origins, an observation that provides biological significance to this ERRa/b-catenin/WNT11 signaling pathway. In addition, functional genomics has identified ERRa target genes involved in invasion and migration and in promoting tumor vascularization such as FGF and CXCR4. 51 ERRg, but not PGC-1a, was shown to directly regulate the expression of E-cadherin and to promote a genetic program characteristic of mesenchymalto-epithelial transition. 60 This observation provides further evidence that the activity of the different components of the PGC/ERR axis can have distinct transcriptional output. The promotion of mesenchymal-to-epithelial transition by ERRg might be related to the correlation of its expression with better prognosis in several types of cancer.
CONCLUDING REMARKS
Studies reviewed herein clearly show that modulation of cellular energy metabolism by the PGC-1/ERR transcriptional axis plays a major role in the process of tumorigenesis. In normal cells, the activity of the PGC-1/ERR axis can be used to increase cellular metabolism, to support the growth of rapidly dividing cells, to direct metabolic programs necessary for cell differentiation and to maintain cellular energy homeostasis in differentiated cells. Indeed, the action of the PGC-1/ERR axis can have both proliferative and anti-proliferative outcomes, which are likely dependent on the composition of the PGC-1/ERR complexes present in these cells. In cancer cells, the activity of the PGC-1/ERR axis is further influenced by oncogenic signals and can thus be re-directed to induce metabolic programs favoring or attenuating cell growth and proliferation ( Figure 2 ). Several questions regarding the role of the PGC-1/ERR axis in tumor development will need to be addressed in the future in order to obtain a more comprehensive view of the impact of this axis on tumor development. In particular, it will be central to decipher the particular roles of the specific PGC-1/ERR pairs in tumors, mostly in setting the metabolic status of cancer cells. Such knowledge would further allow to better assessing which cancers would best benefit from pharmacological targeting of the specific PGC-1/ERR complexes.
While several oncogenes and tumor suppressors have been implicated in the regulation of cancer cell metabolism, the PGC-1/ERR axis has recently emerged as one of the key, and possibly the most significant player in the process leading to the reprogramming of metabolism in tumor cells. Being central to this process and amenable to pharmacologic manipulation, the PGC-1/ ERR axis provides a unique therapeutic opportunity to reprogram, in a comprehensive manner, the networks of metabolic pathways whose activities are deregulated by cancer genes. Figure 2 . Schematic representation of the potential involvement of the PGC-1/ERR axis and its specific components on metabolic output and its consequences on oncogenic progression.
